EMBC - NASDAQ

Embecta Corp.

EMBC·NASDAQ

$3.32

-2.8%

HealthcareDrug Manufacturers - Specialty & Generic

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$196.97M

EPS1.6400

P/E Ratio2.02

Earnings Date08/06/2026

1.09B

Assets

-15%

3Y-

5Y+48.0%

10Y+46.0%

1.74B

Total Liabilities

-14%

3Y-12.0%

5Y+949.0%

10Y+1283.0%

-650.60M

Total Equity

-12%

3Y-27.0%

5Y-214.0%

10Y-213.0%

Embecta Corp. Funding & Solvency Profile

EMBC · NASDAQ

Current Assets

Cash & Cash Equivalents225.50M

Net Receivables148.90M

Inventory178.60M

Other Current Assets3.10M

Total Current Assets631 M

Non-Current Assets

Property, Plant & Equipment48.50M

Goodwill & Intangible Assets22.40M

Long-Term Investments0.00

Other Non-Current Assets368.40M

Total Non-Current Assets417 M

Total Assets

1.09B

Financial Health Analysis

Current Ratio

2.41x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Working Capital

370 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

58% Current

Balanced asset mix between current and non-current assets, typical of many stable businesses.

Embecta Corp. Balance Sheet

EMBC • NASDAQ

Embecta Corp. Balance Sheet	Sep 2025	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020	Sep 2019
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	225.5M	267.5M	326.3M	330.9M	0.0	0.0	0.0
Cash & Short-Term Investments	225.5M	267.5M	326.5M	330.9M	0.0	0.0	0.0
Net Receivables	148.9M	248M	17.9M	23.4M	150.6M	120M	127M
Accounts Receivables	145.6M	194.2M	17.9M	23.4M	150.6M	120M	127M
Other Receivables	3.3M	53.8M	0.0	0.0	0.0	0.0	0.0
Inventory	178.6M	171.5M	152.1M	122.8M	118M	102M	101M
Prepaids	75.3M	0.0	110.2M	77.9M	23.2M	13M	20M
Other Current Assets	3.1M	74M	142.4M	109.7M	200K	0.0	0.0
Total Current Assets	631.4M	761M	749.1M	664.7M	292M	235M	248M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	48.5M	290.4M	323.2M	301.6M	451M	462M	457M
Goodwill	15.4M	15.6M	15.6M	15.7M	16M	16M	16M
Intangible Assets	7M	8.1M	9.1M	8.9M	18M	14M	16M
Goodwill & Intangible Assets	22.4M	23.7M	24.7M	24.6M	34M	30M	32M
Long-Term Investments	0.0	0.0	0.0	-95.5M	-11.4M	0.0	0.0
Tax Assets	20.2M	0.0	0.0	95.5M	11.4M	0.0	0.0
Other Non-Current Assets	368.4M	210.2M	117.4M	95.5M	11M	11M	8M
Total Non-Current Assets	459.5M	524.3M	465.3M	421.7M	496M	503M	497M
Total Assets	1.1B	1.3B	1.2B	1.1B	788M	738M	745M
LIABILITIES
CURRENT LIABILITIES
Total Payables	84M	160.2M	87.1M	41.4M	54.2M	50M	47M
Accounts Payable	74.2M	91M	53.5M	41.4M	54.2M	50M	47M
Other Payables	9.8M	69.2M	33.6M	0.0	0.0	0.0	0.0
Accrued Expenses	49.4M	200.9M	180.2M	48.5M	108.7M	86M	79M
Short Term Debt	12.9M	9.5M	9.5M	9.5M	0.0	1M	0.0
Capital Lease Obligations (Current)	0.0	3.4M	9.5M	3.6M	0.0	0.0	0.0
Tax Payables	0.0	26.7M	33.6M	27.2M	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	33.6M	0.0	0.0	-1M	0.0
Other Current Liabilities	115.2M	0.0	33.6M	198M	1.1M	1M	0.0
Total Current Liabilities	261.5M	374M	353.5M	301M	164M	137M	126M
NON-CURRENT LIABILITIES
Long Term Debt	1.4B	1.6B	1.6B	1.6B	0.0	0.0	0.0
Deferred Revenue (Non-Current)	0.0	0.0	0.0	-46.1M	0.0	0.0	0.0
Deferred Tax Liabilities (Non-Current)	62.6M	11.9M	0.0	46.1M	29.7M	25M	0.0
Other Non-Current Liabilities	0.0	42.2M	57.2M	41.8M	0.0	0.0	0.0
Total Non-Current Liabilities	1.5B	1.6B	1.7B	1.7B	29.7M	29M	0.0
Capital Lease Obligations	28.7M	33.6M	41M	40.5M	0.0	4M	0.0
Total Liabilities	1.7B	2B	2B	2B	194M	166M	126M
SHAREHOLDERS' EQUITY
Common Stock	600K	600K	600K	600K	865M	834M	855M
Additional Paid-In Capital	80M	52.5M	27.9M	10M	0.0	0.0	0.0
Retained Earnings	-445.6M	-498.6M	-541.1M	-577.1M	0.0	0.0	0.0
Accumulated Other Comprehensive Income/Loss	-285.6M	-292.8M	-309.1M	-324.9M	-271M	-262M	-278M
Total Stockholders' Equity	-650.6M	-738.3M	-821.7M	-891.4M	594M	572M	577M
Total Equity	-650.6M	-738.3M	-821.7M	-891.4M	594M	572M	577M
SUMMARY
Total Liabilities & Equity	1.1B	1.3B	1.2B	1.1B	788M	738M	703M
Total Investments	0.0	0.0	0.0	-95.5M	-11.4M	0.0	0.0
Total Debt	1.4B	1.6B	1.6B	1.6B	0.0	5M	0.0
Net Debt	1.2B	1.3B	1.3B	1.3B	0.0	5M	0.0
Shares Outstanding	58,485,119	58,485,119	58,485,119	58,485,119	58,485,119	58,485,119	58,485,119

SEC Filings

EMBC - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 15, 2026	May 15, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 05, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 05, 2026	May 05, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 20, 2026	March 19, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 13, 2026	February 11, 2026	2026	View Filing
10-Q 10-Q 2025 Q4 Q4	February 05, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 05, 2026	February 05, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	December 18, 2025	February 11, 2026	2026	View Filing
10-K 10-K 2025 FY FY	November 25, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 25, 2025	November 25, 2025	2025	View Filing

Showing 1 to 10 of 60 filings

Related Guides

Blog Categories

Continue your EMBC research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.